GlassScriptPhysician profile
Amanda Kuehner
NPI 1942660402
$423.07
in general payments reported to CMS, 2019-2025
11 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $13.54 · 2023: $79.46 · 2024: $75.67 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $146.65 | 2021-2025 | |
| Lilly USA, LLC | $108.07 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $35.09 | 2024-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $26.99 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $18.29 | 2021 | |
| Organogenesis INC. | $18.21 | 2021 | |
| Novo Nordisk INC | $14.88 | 2021 | |
| Sanofi Pasteur INC. | $14.73 | 2025 | |
| Dexcom, INC. | $13.55 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $13.54 | 2022 | |
| Sumitomo Pharma America, INC. | $13.07 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Kuehner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.